doi: 10.1016/j.orcp.2019.03.003 73 YinQ
A novel triple agonist of GLP-1/GIP/Gcg receptor is retatrutide, showing balanced GcgR and GLP1R effect but more GIP effect in vitro
Liver fat reduction, if relevant to your situation, reaches clinically meaningful levels
These symptoms are linked to how the medication slows digestion, as seen with other GLP-1s
a more favorable option for some patients Side Effects: Black Box Warning: RISK OF THYROID C-CELL TUMORS Reference: rxlist.com (Tanzeum) Dulaglutide Drug Name: Trulicity (FDA Approved 9/18/14) GLP-1 receptor agonist, hypoglycemic Pharmacokinetics: Long acting (half life: 5 days) subcutaneous pen injections weekly dosing (vs daily dosing for some other GLP-1 agonists such as exenatide, liraglutide & lixisenatide) a more favorable dosing option for some patients Side Effects: Black Box Warning: RISK OF THYROID C-CELL TUMORS References: Masharani U, Kroon L (2024): Pancreatic Hormones & Antidiabetic Drugs (Chapter 41)
Some of the five-star reviews have a generic quality that makes me skeptical, but the overall score reflects a mostly positive customer base